🇪🇺EU · EMAAuthorised

Ervebo(recombinant vesicular stomatitis virus (strain indiana) with a deletion of the envelope glycoprotein, replaced with the zaire ebolavirus (strain kikwit 1995) surface glycoprotein)

Hemorrhagic Fever, Ebola

Marketing Authorisation Holder: Merck Sharp & Dohme B.V.

EMA Authorisation: 11/11/2019

INN: Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live)

Indication

Ervebo is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus. The use of Ervebo should be in accordance with official recommendations.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Ervebo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Ervebo Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.